Second-line combination chemotherapy with docetaxel and nedaplatin for cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma

Journal of Thoracic Oncology

Volumn 4, Issue 8, 2009, Pages 1017-1021

  Jin, Jianhua ^a   Xu, Xiyuan ^b   Wang, Fang ^a   Yan, Guodu ^a   Liu, Jianyue ^a   Lu, Wenbin ^a   Li, Xianwen ^a   Tucker, Steven Jay ^c   Zhong, Baoliang ^d   Cao, Zhigang ^e   Wang, Daoyuan ^f  

^a JIANGSU UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c Pacific Cancer Centre   (Singapore)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^e SHANGHAI CANCER INSTITUTE   (China)

^f SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Docetaxel; Esophageal squamous cell carcinoma; Nedaplatin; Salvage chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; NEDAPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT FAILURE;

EID: 68349093747     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181add9c7     Document Type: Article

References (31)

1. Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes of resected esophageal cancer. Ann Surg 2002;236:376-384. (Pubitemid 34971347)
2. Kies MS, Rosen ST, Tsang TK, et al. Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer. Cancer 1987;60: 2156-2160.
3. Hilgenberg AD, Carey RW, Wilkins EW Jr, Choi NC, Mathisen DJ, Grillo HC. Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus. Ann Thorac Surg 1988;45:357-363. (Pubitemid 18097321)
4. Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1992;22: 172-176.
5. Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216-1220. (Pubitemid 27359638)
6. Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Semin Oncol 1999;26:12-20.
7. Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001;31:419-423. (Pubitemid 33039748)
8. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349: 2241-2252.
9. Trudeau ME. Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol 1996;6:443-457.
10. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 1998; 9:1-17.
11. Metges J, Hennequin C, Ychou M, et al. Docetaxel as a second-line chemotherapy in metastatic esophageal cancer: a French study. Proc Am Soc Clin Oncol 2001;20:160a (Abstract 635).
12. Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004;15:955-959. (Pubitemid 39004353)
13. Sasaki Y, Shinkai T, Eguchi K, et al. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay. Cancer Chemother Pharmacol 1991;27:263-270.
14. Alberts DS, Fanta PT, Running KL, et al. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Cancer Chemother Pharmacol 1997;39:493-497.
15. Kurita H, Yamamoto E, Nozaki S, Wada S, Furuta I, Kurashina K. Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Oral Oncol 2004;40: 1000-1006. (Pubitemid 39422785)
16. Hirao M, Fujitani K, Tsujinaka T. Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer. Dis Esophagus 2004;17:247-250. (Pubitemid 39377898)
17. Kurata T, Tamura K, Yamamoto N. Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer. Br J Cancer 2004;90:2092-2096. (Pubitemid 38869711)
18. Saito J, Sugawara S, Nakai Y, et al. Phase I/II study of combination chemotherapy with docetaxel and nedaplatin for unresectable non-smallcell lung cancer. Jpn J Lung Cancer 2000;40:513.
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trial 1989;10:1-10. (Pubitemid 19099520)
20. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959;53:457-481.
21. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909. (Pubitemid 46630593)
22. Nicolaou N, Conlan AA. Cyclophosphamide, doxorubicin and celestin intubation for inoperable oesophageal carcinoma. S Afr Med J 1982;61: 428-431.
23. Levard H, Pouliquen X, Hay JM, et al. 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur J Surg 1998;164:849-857.
24. Grünberger B, Raderer M, Schmidinger M, Hejna M. Palliative chemotherapy for recurrent and metastatic esophageal cancer. Anticancer Res 2007;27:2705-2714. (Pubitemid 47227986)
25. Martin MG, Govindan R, Morgensztern D. Second-line therapy for esophageal cancer. Expert Rev Anticancer Ther 2007;7:871-876.
26. Syrigos KN, Zalonis A, Kotteas E, Saif MW. Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev 2008;27:273-288.
27. Osaka Y, Takagi Y, Hoshino S, Tachibana S, Tsuchida A, Aoki T. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting. Dis Esophagus 2006;19:473-476. (Pubitemid 44644684)
28. Kanai M, Matsumoto S, Nishimura T, et al. Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer. Int J Clin Oncol 2007;12:224-227. (Pubitemid 46944642)
29. Kawai Y, Taniuchi S, Okahara S, Nakamura M, Gemba M. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull 2005;28:1385-1388. (Pubitemid 41379685)
30. Ilson DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999;17: 3270-3275. (Pubitemid 29470662)
31. Polee MB, Eskens FA, van der Burg ME, et al. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 2002;86:669-673. (Pubitemid 34250803)